Fundz

Oragenics Appoints Dr. James Kelly as Chief Medical Officer

PUBLIC · OGENMar 18, 2024

Position

Chief Medical Officer

Company

Oragenics

James Kelly
jkelly@oragenics.com
SarasotaBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Description

Oragenics, Inc. appoints Dr. James "Jim" Kelly as its Chief Medical Officer to oversee its upcoming Phase II clinical trial

Quick answer

Oragenics Appoints Dr. James Kelly as Chief Medical Officer (March 18, 2024). Oragenics is based in Sarasota, Florida, United States.

Who is the new Chief Medical Officer at Oragenics?
Oragenics named James Kelly Chief Medical Officer, announced March 18, 2024.
What did Oragenics announce on March 18, 2024?
Oragenics, Inc. appoints Dr. James "Jim" Kelly as its Chief Medical Officer to oversee its upcoming Phase II clinical trial
What does Oragenics do?
Oragenics, Inc. is a biopharmaceutical company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders.
Where is Oragenics based?
Oragenics is based in Sarasota, Florida, United States.
Which similar companies made leadership changes around the same time?
Fulcrum Therapeutics (March 18, 2024), Madrigal Pharmaceuticals (March 11, 2024), Apollomics (March 4, 2024) and Aculys Pharma (April 1, 2024) also announced leadership changes within 45 days of Oragenics.

Source: Fundz verified event record.

Other recent leadership changes in Therapeutics and Pharmaceutical

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Oragenics, and when

A new leader at Oragenics brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Oragenics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Oragenics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Oragenics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Oragenics

Location

4902 Eisenhower Blvd. Suite 125

Sarasota, Florida, United States

About

Oragenics, Inc. is a biopharmaceutical company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders. The company is dedicated to the development of drug candidates for the treatment of mild Traumatic Brain Injury (TBI) and other related neurological conditions.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Oragenics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Michael Sullivan
Likely contact at this company
••••••••@••••••••

See Michael Sullivan's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Oragenics's next move

Learn about Strategic plan

Oragenics changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.